Bio-Gene Technology

Bio-Gene Technology Market capitalization

The The market capitalization of Bio-Gene Technology (BGT.AX) as of Oct 31, 2026 is 9.46 M AUD. In the previous year, The market capitalization was 9.46 M AUD — a change of 0.00% (lower).

Market capitalization

9.46 MAUD

YoY

0.00%

Last updated:

In 2026, Bio-Gene Technology's market cap stood at 9.46 M AUD, a 0.00% increase from the 9.46 M AUD market cap in the previous year.

The Bio-Gene Technology Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2019
9.46 M AUD
Jan 1, 2020
9.46 M AUD
Jan 1, 2021
9.46 M AUD
Jan 1, 2022
9.46 M AUD
Jan 1, 2023
9.46 M AUD
Jan 1, 2024
9.46 M AUD
Jan 1, 2025
9.46 M AUD
Jan 1, 2026
9.46 M AUD
The Bio-Gene Technology Market capitalization history
YEARMarket capitalizationYoY
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD0.00%
9.46 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology Ltd develops and commercializes insecticides using beta-triketone platform technology. The company's lead products are Flavocide, a chemically synthesized insecticide based on flavesone, and Qcide, a natural oil product containing tasmanone extracted from Gympie Messmate leaves via steam distillation. These products address insecticide resistance and toxicity issues in crop protection, storage, public health, animal health, and consumer applications. Insecticide manufacturers purchase the company's platform technology and products for commercialization across multiple sectors. The firm's beta-triketone platform provides multiple solutions for insecticide manufacturers seeking to develop novel pest control products. Flavocide and Qcide represent the company's primary commercial offerings, with Flavocide targeting synthetic insecticide markets and Qcide focusing on natural oil-based solutions. The company's technology enables the development of targeted insect control solutions for various applications including agricultural crop protection and public health management. Bio-Gene Technology Ltd. aims to develop a portfolio of targeted insect control solutions for insecticide manufacturers. The company's platform technology allows manufacturers to create new products addressing resistance and toxicity challenges. Through its two lead products, the company provides both synthetic and natural options for the insecticide market, targeting manufacturers who seek innovative solutions for pest management across different industry segments. Bio-Gene Technology is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Bio-Gene Technology's Market Capitalization

Bio-Gene Technology's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Bio-Gene Technology's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Bio-Gene Technology's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Bio-Gene Technology’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Bio-Gene Technology stock

The market capitalization of Bio-Gene Technology is 9.46 M AUD in 2026.

The market capitalization of Bio-Gene Technology changed from 9.46 M AUD to 9.46 M AUD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's AUD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' AUD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Bio-Gene Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Bio-Gene Technology

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Bio-Gene Technology